Literature DB >> 25952493

Treating chemotherapy-induced thrombocytopenia: is it time for oncologists to use thrombopoietin agonists?

Mojibade N Hassan, Edmund K Waller.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25952493      PMCID： PMC4659425     

Source DB:  PubMed          Journal:  Oncology (Williston Park)        ISSN： 0890-9091            Impact factor:   2.990


× No keyword cloud information.
  11 in total

1.  Thrombopoietin is synthesized by bone marrow stromal cells.

Authors:  A Guerriero; L Worford; H K Holland; G R Guo; K Sheehan; E K Waller
Journal:  Blood       Date:  1997-11-01       Impact factor: 22.113

2.  Weighing the hazards of erythropoiesis stimulation in patients with cancer.

Authors:  Fadlo R Khuri
Journal:  N Engl J Med       Date:  2007-06-14       Impact factor: 91.245

3.  Thrombocytopenia caused by the development of antibodies to thrombopoietin.

Authors:  J Li; C Yang; Y Xia; A Bertino; J Glaspy; M Roberts; D J Kuter
Journal:  Blood       Date:  2001-12-01       Impact factor: 22.113

4.  Romiplostim for management of chemotherapy-induced thrombocytopenia.

Authors:  R Parameswaran; M Lunning; S Mantha; S Devlin; A Hamilton; G Schwartz; G Soff
Journal:  Support Care Cancer       Date:  2014-01-12       Impact factor: 3.603

5.  Eltrombopag, a thrombopoietin receptor agonist, enhances human umbilical cord blood hematopoietic stem/primitive progenitor cell expansion and promotes multi-lineage hematopoiesis.

Authors:  Hongliang Sun; Ying Tsai; Irena Nowak; Jane Liesveld; Yuhchyau Chen
Journal:  Stem Cell Res       Date:  2012-05-14       Impact factor: 2.020

6.  Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor.

Authors:  Russell L Basser; Elizabeth O'Flaherty; Michael Green; Maria Edmonds; Janet Nichol; Dora M Menchaca; Brian Cohen; C Glenn Begley
Journal:  Blood       Date:  2002-04-01       Impact factor: 22.113

Review 7.  Managing thrombocytopenia associated with cancer chemotherapy.

Authors:  David J Kuter
Journal:  Oncology (Williston Park)       Date:  2015-04       Impact factor: 2.990

Review 8.  Milestones in understanding platelet production: a historical overview.

Authors:  David J Kuter
Journal:  Br J Haematol       Date:  2014-02-14       Impact factor: 6.998

9.  Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer.

Authors:  Dawn L Hershman; Donna L Buono; Jennifer Malin; Russell McBride; Wei Yann Tsai; Alfred I Neugut
Journal:  J Natl Cancer Inst       Date:  2009-11-10       Impact factor: 13.506

10.  Bone marrow fibrosis in 66 patients with immune thrombocytopenia treated with thrombopoietin-receptor agonists: a single-center, long-term follow-up.

Authors:  Waleed Ghanima; Julia Turbiner Geyer; Christina S Lee; Leonardo Boiocchi; Allison A Imahiyerobo; Attilio Orazi; James B Bussel
Journal:  Haematologica       Date:  2014-01-24       Impact factor: 9.941
View more
  4 in total

Review 1.  From chronic immune thrombocytopenia to severe aplastic anemia: recent insights into the evolution of eltrombopag.

Authors:  Harinder Gill; Raymond S M Wong; Yok-Lam Kwong
Journal:  Ther Adv Hematol       Date:  2017-02-01

2.  Carboplatin-Induced Thrombocytopenia through JAK2 Downregulation, S-Phase Cell Cycle Arrest and Apoptosis in Megakaryocytes.

Authors:  Yi-Hong Wu; Hsing-Yu Chen; Wei-Chin Hong; Chen-Ying Wei; Jong-Hwei Su Pang
Journal:  Int J Mol Sci       Date:  2022-06-03       Impact factor: 6.208

3.  Shen-Cao granules formulated based on traditional Chinese medicine alleviates bone marrow suppression caused by platinum-based anticancer reagents.

Authors:  Chunfeng Yu; Zhonghua Jiang; Aihua Hou; Yuejun Mu; Wei Liu; Song Tan
Journal:  Medicine (Baltimore)       Date:  2017-05       Impact factor: 1.889

4.  Exosomal miR-122-5p is Related to the Degree of Myelosuppression Caused by Chemotherapy in Patients with Colorectal Cancer.

Authors:  Jinbao Chen; Wentao Wu; Xue He; Linlin Jia; Jiahua Yang; Xianke Si; Kun Yu; Sen Li; Yanyan Qiu; Ke Xu; Peihao Yin; Yijun Cao; Qiong Li; Wei Li
Journal:  Cancer Manag Res       Date:  2021-11-03       Impact factor: 3.989
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.